Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo
- 29 August 2016
- journal article
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 54 (1) , 53-61
Abstract
Histone deacetylase (HDAC) inhibition mediated by small molecule HDAC inhibitors (HDACi) has demonstrated divergent effects including toxicity towards transformed cell lines, neuroprotection in neurological disease models, and inhibition of oligodendrocyte precursor cell (OPC) differentiation to mature oligodendrocytes (OL). However, it remains unknown if transient HDAC inhibition may promote OPC survival. Using mouse cortical OPC primary cultures, we investigated the effects of the FDA approved pan-HDACi suberoylanilide hydroxamic acid (SAHA) on OPC survival. Initial studies showed differences in the HDAC expression pattern of multiple HDAC isoforms in OPCs relative to their terminally differentiated progeny cells, OLs and astrocytes. Treatment of OPCs with SAHA for up to 72h using a maximum concentration either at or lower than those necessary for cytotoxicity in most transformed cell lines resulted in over 67% reduction in viability relative to vehicle-treated OPCs. This was at least partly due to increased apoptosis as SAHA-treated cells displayed activated caspase 3 and were protected by the general caspase inhibitor Q-VD-OPH. Additionally, SAHA treatment of whole mice at postnatal day 5 induced apoptosis of cortical OPCs. These results suggest that SAHA negatively impacts OPC survival and may be detrimental to the myelinating brain and spinal cord. Such toxicity may be relevant in a clinical context as SAHA is currently involved in numerous clinical trials and is in consideration for use in the treatment of psychiatric and neurodegenerative conditions.Keywords
Funding Information
- Kentucky Spinal Cord and Head Injury Research Trust, the Commonwealth of Kentucky Challenge for Excellence (NS054708, RR15576/GM103507)
This publication has 67 references indexed in Scilit:
- Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblastsBone, 2011
- Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myelomaBritish Journal of Cancer, 2011
- Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibitionBrain Research, 2010
- HDAC inhibitors and neurodegeneration: At the edge between protection and damagePharmacological Research, 2010
- Deregulation of HDAC1 by p25/Cdk5 in NeurotoxicityNeuron, 2008
- NG2 cell response in the CNP‐EGFP mouse after contusive spinal cord injuryGlia, 2008
- Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiencyNature Neuroscience, 2008
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology, 2008
- Post-Translational Modifications of Nucleosomal Histones in Oligodendrocyte Lineage Cells in Development and DiseaseJournal of Molecular Neuroscience, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006